Vimarsana
Biggest News Aggregation in the World

Page 8 - Arnold Ventures News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Arnold Ventures. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Arnold Ventures Today - Breaking & Trending Today

Patients see first savings from Biden's drug price push, as pharma lines up its lawyers - Vimarsana News

Patients see first savings from Biden's drug price push, as pharma lines up its lawyers

Last year alone, David Mitchell paid $16,525 for 12 little bottles of Pomalyst, one of the pricey medications that treat his multiple myeloma, a blood cancer he was diagnosed with in 2010. The drugs h...

Source: theday.com
Patients see first savings from Biden's drug price push, as pharma lines up its lawyers | Health - Vimarsana News

Patients see first savings from Biden's drug price push, as pharma lines up its lawyers | Health

Last year alone, David Mitchell paid $16,525 for 12 little bottles of Pomalyst, one of the pricey medications that treat his multiple myeloma, a blood cancer he was diagnosed with

In fight over Medicare payments, the hospital lobby shows its strength - Vimarsana News

In fight over Medicare payments, the hospital lobby shows its strength

A policy known as site-neutral payment has sparked a ferocious lobbying battle in the Senate, with hospitals determined to kill such legislation.

Patients See First Savings From Biden's Drug Price Push, as Pharma Lines Up Its Lawyers - Vimarsana News

Patients See First Savings From Biden's Drug Price Push, as Pharma Lines Up Its Lawyers

A restructuring of the Medicare drug benefit has wiped out big drug bills for people who need expensive medicines. But the legal battle over drug negotiations means uncertainty over long-term savings.

More money, more new models for AI, but weak guidance plagues enterprise earnings - Vimarsana News

More money, more new models for AI, but weak guidance plagues enterprise earnings

More money, more new models for AI, but weak guidance plagues enterprise earnings - SiliconANGLE